FERRING Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FERRING, and when can generic versions of FERRING drugs launch?
FERRING has seventeen approved drugs.
There are twenty US patents protecting FERRING drugs.
There are two hundred and seventy-seven patent family members on FERRING drugs in forty countries and twenty-two supplementary protection certificates in ten countries.
Summary for FERRING
| International Patents: | 277 |
| US Patents: | 20 |
| Tradenames: | 17 |
| Ingredients: | 8 |
| NDAs: | 17 |
| Patent Litigation for FERRING: | See patent lawsuits for FERRING |
Drugs and US Patents for FERRING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | DDAVP | desmopressin acetate | INJECTABLE;INJECTION | 018938-002 | Apr 25, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Ferring | CONCENTRAID | desmopressin acetate | SOLUTION;NASAL | 019776-001 | Dec 26, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | DISCN | Yes | No | 7,560,429 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FERRING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | 9,220,747 | ⤷ Sign Up |
| Ferring Pharms Inc | DDAVP | desmopressin acetate | TABLET;ORAL | 019955-002 | Sep 6, 1995 | 7,022,340 | ⤷ Sign Up |
| Ferring Pharms Inc | CERVIDIL | dinoprostone | INSERT, EXTENDED RELEASE;VAGINAL | 020411-001 | Mar 30, 1995 | 4,931,288 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FERRING drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and12 g | ➤ Subscribe | 2019-02-11 |
| ➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and 12 g | ➤ Subscribe | 2014-05-21 |
International Patents for FERRING Drugs
Supplementary Protection Certificates for FERRING Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2782584 | 132021000000197 | Italy | ⤷ Sign Up | PRODUCT NAME: ESTRADIOLO (17SS-ESTRADIOLO) IN PARTICOLARE NELLA FORMA EMIIDRATA, E PROGESTERONE COMPRENDENTI LE VARIE FORME DI ESTRADIOLO (17SS-ESTRADIOLO), QUALI LE FORME IDRATE E SOLVATATE, INCLUDENDO LA FORMA EMIIDRATA, ED I SUOI SALI.(BIJUVA); AUTHORISATION NUMBER(S) AND DATE(S): BE582231, 20210406;048335018 -048335020, 20210517 |
| 1003774 | C01003774/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: DEGARELIX; REGISTRATION NUMBER/DATE: SWISSMEDIC 59455 12.02.2010 |
| 2782584 | 301153 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
